Top Suppliers:I want be here


204326-43-2

204326-43-2 structure
204326-43-2 structure
  • Name: NS-2028
  • Chemical Name: 4h-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
  • CAS Number: 204326-43-2
  • Molecular Formula: C9H5BrN2O3
  • Molecular Weight: 269.052
  • Catalog: Signaling Pathways GPCR/G Protein Guanylate Cyclase
  • Create Date: 2018-12-24 17:47:33
  • Modify Date: 2025-08-21 14:07:19
  • NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC50 values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity[1]. NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase with IC50 values of 17 nM and 20 nM[1]. NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells with an IC50 of 30 nM[1]. NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM)[1]. NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability[2].

Name 4h-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one
Synonyms 4H-8-BROMO-1,2,4-OXADIAZOLO(3,4-D)BENZO(B)(1,4)OXAZIN-1-ONE
8-BROMO-4H-2,5-DIOXA-3,9B-DIAZA CYCLOPENTA[A]NAPHTHALEN-1-ONE
Kartogenin
4H-8-Bromo-1,2,4-oxadiazolo[3,4-d]benz[b][1,4]oxazin-1-one
NS-2028
1H,4H-[1,2,4]Oxadiazolo[3,4-c][1,4]benzoxazin-1-one, 8-bromo-
8-Bromo-4H-[1,2,4]oxadiazolo[3,4-c][1,4]benzoxazin-1-one
Description NS-2028 is a highly selective soluble Guanylyl Cyclase (sGC) inhibitor with IC50 values of 30 nM and 200 nM for basal and NO-stimulated enzyme activity[1]. NS-2028 inhibits soluble Guanylyl Cyclase activity in homogenates of mouse cerebellum and neuronal NO synthase with IC50 values of 17 nM and 20 nM[1]. NS-2028 inhibits 3-morpholino-sydnonimine (SIN-1)-elicited formation of cyclic GMP in human cultured umbilical vein endothelial cells with an IC50 of 30 nM[1]. NS-2028 is commonly used in the research of nitric oxide signaling pathways, it inhibits NO-dependent relaxant responses in non-vascular smooth muscle completely (1 μM)[1]. NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability[2].
Related Catalog
Target

IC50: 30 nM (soluble Guanylyl Cyclase sGC)[1]

In Vitro NS-2028 (10 μM; 24 hours) inhibits 25% cell number in comparation with those grown in the presence of vehicle[2]. NS-2028 (10 μM; 30 mins) attenuates VEGF-induced EC migration by inhibiting p38 MAPK activation[2]. Cell Proliferation Assay[2] Cell Line: HUVEC cells Concentration: 10 μM Incubation Time: 24 hours Result: Decreased cell numbers in culture. Western Blot Analysis[2] Cell Line: HUVEC cells Concentration: 10 μM Incubation Time: 30 mins Result: Attenuated VEGF-enhanced p38 phosphorylation.
In Vivo NS-2028 (Deliver orally; 1 g/L; 8 days) exhibits a significant reduction of new vessel formation in the avascular rabbit cornea in response to VEGF pellet implants[2]. Animal Model: Rabbit[2] Dosage: 1 g/L Administration: Deliver orally; 1g/L; 8 days Result: Inhibits VEGF-induced angiogenesis in vivo.
References

[1]. Olesen SP, et al. Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309.

[2]. Morbidelli L, et al. The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability. Am J Physiol Regul Integr Comp Physiol. 2010 Mar;298(3):R824-32.

Density 2.1±0.1 g/cm3
Boiling Point 353.8±52.0 °C at 760 mmHg
Melting Point 161-162ºC
Molecular Formula C9H5BrN2O3
Molecular Weight 269.052
Flash Point 167.8±30.7 °C
Exact Mass 267.948334
PSA 57.26000
LogP 0.27
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.778
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xi
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.